Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report.

Aubrey JM, Benner C, Lam GT

Journal of cardiothoracic surgery12 Jun 2026

PMID42286576 (opens in a new tab)PMCIDPMC13505130 (opens in a new tab)DOI10.1186/s13019-026-04214-6 (opens in a new tab)PepBankPUB-42286576
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a woman in her 50s, severe nausea, emesis and acute chest pain occurred after restarting semaglutide 2.4 mg weekly without titration.

    In plain wordsIn one woman, severe nausea, vomiting and chest pain started after she restarted semaglutide at the full dose without building up.

    Peptide
    Semaglutide
    Outcome
    IncreaseSevere nausea and emesis after restarting semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    A previously healthy woman in her 50s presented with vasopressor dependent shock and respiratory failure requiring intubation following severe nausea, emesis, and acute chest pain.
    1 context sentence
    Summary · context
    She had restarted semaglutide at the maximum 2.4 mg weekly dose the day prior to symptom onset, after several months off therapy and without dose titration.
  2. 02HumanCase report or seriesSafety outcome

    In a woman in her 50s, a contained esophageal perforation was confirmed after restarting semaglutide 2.4 mg weekly without titration.

    In plain wordsIn one woman, a tear in the food pipe was found after she restarted semaglutide at the full dose without building up.

    Peptide
    Semaglutide
    Outcome
    IncreaseEsophageal perforation (Boerhaave's syndrome)
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Esophagram confirmed a contained esophageal perforation.
    1 context sentence
    Summary · context
    She had restarted semaglutide at the maximum 2.4 mg weekly dose the day prior to symptom onset, after several months off therapy and without dose titration.
  3. 03HumanCase report or seriesSafety outcome

    In a woman in her 50s who had a contained esophageal perforation after restarting semaglutide 2.4 mg weekly, readmission two months later showed necrotizing pneumonia and an esophagopleural fistula.

    In plain wordsIn one woman, a lung infection and an abnormal food pipe channel were found two months after her food pipe tear.

    Peptide
    Semaglutide
    Outcome
    IncreaseReadmission with necrotizing pneumonia and esophagopleural fistula
    Study

    n = 1

    Outcome group
    Adverse events · Respiratory
    Studied dose
    2.4 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Two months later, she was readmitted with necrotizing pneumonia. Imaging and endoscopy revealed an esophagopleural fistula, abscess, and migrated stent.
    1 context sentence
    Summary · context
    She had restarted semaglutide at the maximum 2.4 mg weekly dose the day prior to symptom onset, after several months off therapy and without dose titration.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.